Premium
Mankind Pharma Ltd plans to raise over Rs 9,000 crore ($1.2 billion) through non-convertible debentures (NCDs) and short-term commercial paper to fund its Rs 13,630 crore acquisition of Bharat Serums and Vaccines Ltd (BSV), a media report said. The company is expected to borrow at an average cost of around 8.5%, with maturities ranging ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
